Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experienceHagop M. Kantarjian, Jörge E. Cortes, Susan O’Brien et al.|Blood|2012Cited by 340
Chemometric approaches to improve PLSDA model outcome for predicting human non-alcoholic fatty liver disease using UPLC-MS as a metabolic profiling toolAlfonso Quintás‐Cardama, Agustín Lahoz, José V. Castell et al.|Metabolomics|2011Cited by 59
Evaluation of the effect of chance correlations on variable selection using Partial Least Squares-Discriminant AnalysisJulia Kuligowski, Alfonso Quintás‐Cardama, Javier Escobar et al.|Talanta|2013Cited by 23
Predicting Outcomes in Patients With Chronic Myeloid Leukemia at Any Time During Tyrosine Kinase Inhibitor TherapyAlfonso Quintás‐Cardama, Jörge E. Cortes, Xuelin Huang et al.|Clinical Lymphoma Myeloma & Leukemia|2014Cited by 16